Covered recipient · General Payments record
JESSICA LEE BETANCOURT
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2024
$3,583.56
- Reported across 138 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $608.96 | 30 |
| Education | $27.78 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $108.31 | 6 |
| Amgen Inc. | $93.22 | 5 |
| Insulet Corporation | $80.66 | 3 |
| Novo Nordisk AS | $57.12 | 3 |
| DEXCOM, INC. | $53.90 | 3 |
| ABBVIE INC. | $48.13 | 2 |
| Nevro Corp. | $40.73 | 2 |
| Kyowa Kirin, Inc. | $28.99 | 1 |
| Abbott Laboratories | $21.15 | 1 |
| Astellas Pharma US Inc | $20.10 | 1 |
| Medtronic, Inc. | $17.53 | 1 |
| Amneal Pharmaceuticals LLC | $17.35 | 1 |
| Radius Health, Inc. | $17.17 | 1 |
| RECORDATI_RARE_DISEASES_INC. | $16.80 | 1 |
| Corcept Therapeutics | $15.58 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (32)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $21.15 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125166592 | CMS |
| ABBVIE INC. | $22.94 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103317692 | CMS |
| ABBVIE INC. | $25.19 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103317694 | CMS |
| Amgen Inc. | $13.89 | 01/18/2024 | Education | Undisputed | 01/23/2026 | 1117506660 | CMS |
| Amgen Inc. | $19.09 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111529472 | CMS |
| Amgen Inc. | $30.71 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111529474 | CMS |
| Amgen Inc. | $15.64 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111529470 | CMS |
| Amgen Inc. | $13.89 | 05/29/2024 | Education | Undisputed | 01/23/2026 | 1117506662 | CMS |
| Amneal Pharmaceuticals LLC | $17.35 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139180469 | CMS |
| Astellas Pharma US Inc | $20.10 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139275580 | CMS |
| Corcept Therapeutics | $15.58 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117759233 | CMS |
| Dexcom, Inc. | $17.85 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153308477 | CMS |
| Dexcom, Inc. | $14.12 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153308479 | CMS |
| Dexcom, Inc. | $21.93 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153308481 | CMS |
| Insulet Corporation | $20.10 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116797183 | CMS |
| Insulet Corporation | $27.69 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116797181 | CMS |
| Insulet Corporation | $32.87 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116821344 | CMS |
| Kyowa Kirin, Inc. | $28.99 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127032535 | CMS |
| Lilly USA, LLC | $15.53 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135066149 | CMS |
| Lilly USA, LLC | $22.28 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135066153 | CMS |
| Lilly USA, LLC | $15.32 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135063633 | CMS |
| Lilly USA, LLC | $19.47 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135021116 | CMS |
| Lilly USA, LLC | $16.86 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135046534 | CMS |
| Lilly USA, LLC | $18.85 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135066151 | CMS |
| Medtronic, Inc. | $17.53 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119414162 | CMS |
| Nevro Corp. | $19.96 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130727652 | CMS |
| Nevro Corp. | $20.77 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130727654 | CMS |
| Novo Nordisk Inc | $20.55 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097243984 | CMS |
| Novo Nordisk Inc | $19.58 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097468633 | CMS |
| Novo Nordisk Inc | $16.99 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097827780 | CMS |
| Radius Health, Inc. | $17.17 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089960964 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $16.80 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139161366 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.